SecurityCBS / CBS Corp. (124857202)
Chairman, President & CEOMOONVES LESLIE
Form 4 Count940
Form 425 Count89
Form 8-K Count88
Form SC 13G/A Count22

SEC Filings - 10K, 8K, Annual Reports

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CBS Corp.


DateFormTitle
2018-09-10 8-K CBS / CBS Corp. FORM 8-K (Current Report)
2018-08-02 8-K CBS / CBS Corp. 8-K (Current Report)
2018-08-02 10-Q CBS / CBS Corp. 10-Q (Quarterly Report)
2018-07-30 DEFA14A CBS / CBS Corp. DEFA14A
2018-07-30 8-K CBS / CBS Corp. 8-K (Current Report)
2018-06-29 11-K CBS / CBS Corp. 11-K
2018-06-22 DEF 14C CBS / CBS Corp. null
2018-07-21 LETTER CBS / CBS Corp. null
2018-06-15 PRER14C CBS / CBS Corp. PRER14C
2018-07-21 CORRESP CBS / CBS Corp. null
2018-07-21 LETTER CBS / CBS Corp. null
2018-07-21 LETTER CBS / CBS Corp. null
2018-07-21 CORRESP CBS / CBS Corp. null
2018-06-06 DEFA14A CBS / CBS Corp. DEFA14A
2018-06-06 8-K CBS / CBS Corp. 8-K (Current Report)
2018-05-28 PRE 14C CBS / CBS Corp. PRE 14C
2018-05-22 8-K CBS / CBS Corp. 8-K (Current Report)
2018-05-18 8-K CBS / CBS Corp. null (Current Report)
2018-05-14 8-K CBS / CBS Corp. 8-K (Current Report)
2018-05-04 10-Q CBS / CBS Corp. 10-Q (Quarterly Report)
2018-05-03 8-K CBS / CBS Corp. 8-K (Current Report)
2018-04-06 DEFA14A CBS / CBS Corp. DEFA14A
2018-04-06 DEF 14A CBS / CBS Corp. DEF 14A
2018-03-02 S-4 CBS / CBS Corp. S-4
2018-03-02 S-4 CBS / CBS Corp. S-4
2018-02-20 10-K CBS / CBS Corp. 10-K (Annual Report)
2018-02-15 8-K CBS / CBS Corp. 8-K (Current Report)
2018-02-09 S-8 POS CBS / CBS Corp. S-8 POS
2018-02-08 SC 13G/A CBS / CBS Corp. / VANGUARD GROUP INC - 3G/A (Passive Investment)
2018-02-08 SC 13G/A CBS / CBS Corp. / VANGUARD GROUP INC - 3G/A (Passive Investment)
2018-02-08 SC 13G/A CBS / CBS Corp. / BlackRock Inc. - 3G/A (Passive Investment)
2018-02-08 SC 13G/A CBS / CBS Corp. / BlackRock Inc. - 3G/A (Passive Investment)
2017-05-24 8-K CBS 8-K (Current Report/Significant Event)
2017-05-04 10-Q CBS 10-Q (Quarterly Report)
2017-05-04 8-K CBS 8-K (Current Report/Significant Event)
2017-04-07 DEFA14A CBS DEFA14A
2017-04-07 DEF 14A CBS DEF 14A
2017-03-20 425 CBS 425 (Prospectus)
2017-03-02 425 CBS 425 (Prospectus)
2017-02-17 10-K CBS 10-K (Annual Report)
2017-02-15 8-K CBS 8-K (Current Report/Significant Event)
2017-02-10 SC 13G/A CBS 3G/A (Passive Acquisition of More Than 5% of Shares)
2017-02-10 SC 13G/A CBS 3G/A (Passive Acquisition of More Than 5% of Shares)
2017-02-02 8-K CBS FORM 8-K (Current Report/Significant Event)
2017-02-02 425 CBS FORM 8-K (Prospectus)
2017-02-02 425 CBS 425 (Prospectus)
2017-02-02 8-K CBS 8-K (Current Report/Significant Event)
2017-02-02 425 CBS 8-K (Prospectus)
2017-01-23 SC 13G/A CBS 3G/A (Passive Acquisition of More Than 5% of Shares)
2017-01-23 SC 13G/A CBS 3G/A (Passive Acquisition of More Than 5% of Shares)

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 124857202